Aptamer-Peptide Conjugates as Targeted Chemosensitizers for Breast Cancer Treatment

Yan Tan,Yingying Li,Yi-Xin Qu,Yuanye Su,Yongbo Peng,Zilong Zhao,Ting Fu,Xue-Qiang Wang,Weihong Tan

DOI: https://doi.org/10.1021/acsami.0c18282

2020-12-11

Abstract:High levels of heat shock protein 70 (HSP70) in tumors are commonly associated with poor prognosis, enhanced doxorubicin (DOX)-induced cardiotoxicity, and even drug resistance in DOX-related cancer chemotherapy. Several peptides possess remarkable protein inhibition and chemosensitization effects, which are attributed to their specific targeting ability against HSP70. However, the inherent poor cell penetration capacity considerably restricts the biomedical applications of these peptides. We herein describe the design and development of anti-MUC1 aptamer-peptide conjugates (ApPCs) as targeted chemosensitizers to overcome the above-mentioned issues. Moreover, DOX could be loaded on the ApPC to deliver the DOX-enclosed agent ApPC-DOX, which simultaneously acts as a targeted chemosensitizer and anticancer agent for combating drug resistance in breast cancer therapy. This innovative, engineered biocompatible conjugate not only enhances the sensitivity of DOX-resistant cells but also alleviates cardiotoxicity of DOX <i>in vivo</i>, highlighting the success of this targeted chemosensitizer strategy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c18282?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c18282</a>.DNA and peptide sequences; characterization and identification of ApPC and ApPC-DOX <i>in vitro</i> and cellular uptake efficiency of the conjugate; investigation of endocytic pathways; cell viability and <i>in vivo</i> imaging of the conjugate; and measurement of cardiotoxicity related enzymes in the blood (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c18282/suppl_file/am0c18282_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

materials science, multidisciplinary,nanoscience & nanotechnology

What problem does this paper attempt to address?

The paper primarily aims to address the following two key issues:

1. **Overcoming Doxorubicin (DOX) resistance in breast cancer treatment**: DOX is a widely used chemotherapeutic drug, but it faces drug resistance issues in breast cancer treatment. High expression of Heat Shock Protein 70 (HSP70) is associated with DOX resistance and poor prognosis. Researchers have designed a targeted chemosensitizer based on aptamer-peptide conjugates (ApPCs) to overcome this problem.

2. **Reducing DOX-induced cardiotoxicity**: The dose-dependent cardiotoxicity of DOX limits its clinical application. By blocking the action of extracellular HSP70, DOX-induced cardiac dysfunction can be alleviated. Researchers have developed an innovative biocompatible conjugate that not only increases the sensitivity of DOX-resistant cells to the drug but also reduces DOX-induced cardiotoxicity.

To achieve these goals, researchers designed and synthesized aptamer-peptide conjugates (ApPCs) targeting MUC1, which include peptides (P8 or P17) targeting HSP70. These ApPCs can load DOX to form ApPC-DOX complexes and serve as targeted chemosensitizers and anticancer agents for breast cancer treatment. In this way, ApPC-DOX can effectively deliver DOX to breast cancer cells, enhancing its antitumor activity while reducing DOX's cardiac side effects. Additionally, the study explored the specific mechanisms of ApPCs entering target cells and validated their efficacy both in vitro and in vivo.